CLICK HERE FOR PRESCRIBING INFORMATION
*LOSEC is the only prescription medication that is approved for use in dyspepsia.
Dyspepsia: a complex of symptoms which may be caused by any of the following organic diseases: duodenal ulcer, gastric ulcer, NSAID-associated gastric and duodenal ulcers, reflux esophagitis, symptomatic gastroesophageal reflux disease (GERD) i.e., heartburn and regurgitation, or upon investigation no identifiable organic cause is found (i.e., functional dyspepsia).
A working definition of dyspepsia would include the presence of epigastric pain/discomfort, with or without heartburn and regurgitation which may be accompanied by nausea, vomiting, bloating, belching, flatulence, early satiety or post-prandial fullness. Symptoms may occur either during the day or throughout the night.
† If after 2 weeks’ treatment the patient does not respond to therapy, or there is an early clinical indication of a lack of efficacy, the patient should be thoroughly investigated in order to rule out organic disease.1
‡ Prior to treating it should be determined that symptoms are originating from the UGI tract. Patients with alarm symptoms and older patients are at a greater risk of having serious organic disease and should be investigated prior to initiation of therapy. If there is a diagnosis of organic disease, the appropriate treatment regimen should be employed.
The following adverse events (at a rate of more than 1%) have been reported in individuals receiving omeprazole capsules in controlled clinical situations: diarrhea (2.8%); headache (2.6%); flatulence (2.3%); abdominal pain (1.7%); constipation (1.3%); dizziness/vertigo (1.1%).
Reference:
1. PrLOSEC® (omeprazole magnesium) Product Monograph. AstraZeneca Canada Inc.
LOSEC® (omeprazole magnesium) is a registered trademark of AstraZeneca PLC.
The AstraZeneca logo is a trademark of AstraZeneca PLC and is used under license by AstraZeneca Canada Inc.